CN1471932A - Medicine for transient cerebral ischemia attack and its preparation - Google Patents
Medicine for transient cerebral ischemia attack and its preparation Download PDFInfo
- Publication number
- CN1471932A CN1471932A CNA021256845A CN02125684A CN1471932A CN 1471932 A CN1471932 A CN 1471932A CN A021256845 A CNA021256845 A CN A021256845A CN 02125684 A CN02125684 A CN 02125684A CN 1471932 A CN1471932 A CN 1471932A
- Authority
- CN
- China
- Prior art keywords
- tia
- parts
- medicine
- active ingredient
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A Chinese medicine for treating transient ischemic attack (TIA) and preventing cerebral apoplexy is prepared from 5 Chinese-medicinal materials including earthworm, Chuan-xiong rhizome, sophora bud, leech, etc through extracting, volatile oil, decocting, filtering, depositing, concentrating, drying, pulverizing, mixing, sterilizing and loading in capsules. Its advantages are high curative effect, and no by-effect.
Description
The present invention relates to a kind of medicine for the treatment of transient ischemic attack, be basic material specifically with the pure natural animal and plant, through the natural Chinese medicines preparation of modern science advanced technology extraction active ingredient preparation of compositions, the invention still further relates to the preparation method of this natural Chinese medicines preparation.
Transient ischemic attack (TIA) is a kind of transience, reversibility, focal cerebral blood flow circulatory disturbance, in close relations with complete apoplexy, be the omen disease of the apoplexy (apoplexy) of serious harm human health, so world the world of medicine is considered as tendency or " the early stage warning signal " of apoplexy to it!
The TIA sickness rate is about 68,/10 ten thousand, account for about 9.7% in the cerebrovascular, China is lower than the West Europe sickness rate, and have and increase trend year by year, patients with cerebral apoplexy has TIA medical history person about 12.9%～14.8%, send out the age well at middle aged after-stage, 40 years old～see 68 years old more, men and women's ratio 3: 1.3, most with hypertension, hyperlipemia, high blood clotting disease, arteriosclerosis, heart disease and diabetes, morbidity slowly increases the weight of gradually, it is hurried to fall ill occasionally, sings and symptoms is everlasting and is developed to the danger peak in several seconds or several minutes, forms thrombosis and obstruction and causes cerebral infarction, crisis such as cerebral hemorrhage are when the vitals (heart, brain, kidney) day of infarction, being exactly in the dying of people, is that human health is threatened the fierce and cruel killer also more severe than cancer.
At present, the primary disease Drug therapy is run into following difficulty both at home and abroad
1, the medicine of treatment TIA is few, and types of drugs with strong points evident in efficacy still less and has the just sticking side reaction of feeling sick of some upset in the stomachs, and sufferer has the fear ambivalence.
2, use infringement liver, kidney for a long time because of some drugs, produce toleration.
3, the Western medicine aspirin of now having generally acknowledged, warfarin have reasonable curative effect to the prevention cerebral infarction, but invalid to the cerebral hemorrhage paralytic, also can increase once more the hazardness in apoplexy, and certain side reaction is arranged.
The object of the present invention is to provide the new Chinese medicine of a kind of safe, effective, controlled, stable, lasting pure natural, be a kind of adjustment blood lipid metabolism that has concurrently, bring high blood pressure down, reduce blood viscosity, the sclerosis of anti-tremulous pulse medicated porridge, antithrombotic forms, treatment TIA blocks febrile disease, reverses the state of an illness, prevention reduces the agent that the development treatment takes place apoplexy.
Another object of the present invention provides the preparation method of this TIA therapeutic agent.
Solution of the present invention is based on Chinese and western medical science and the understanding of the pathogenetic gene mechanism of TIA and the author are gone through the more than two decades clinical observation proposes new blood circulation and removing stasis; eliminating phlegm hinders the Therapeutic Principle of easypro convulsion a surname of collateral dredging numbness thromboembolism preventing clearly; from the natural Chinese medicines storehouse; go out dredge the meridian passage through thousands of repeated screenings; the stasis of blood pure Chinese medicine of ruton of dispelling; by the theory of Chinese medical science monarch; minister; assistant makes prescription; abide by modern bioscience advanced technology extraction active ingredient compositions; make its performance reducing blood pressure and regulating blood lipid; anticoagulant; thrombolytic; reduce blood " dense; sticking; as to coagulate; poly-" degree; it is unbalance to regulate prostacyclin and thromboxane system; anticoagulant; blood vessel dilating; microcirculation improvement; the cerebral blood flow increasing amount; the blood that improves brain supplies; oxygen supplies and the protection endotheliocyte; alleviate cerebral edema; the Fructus Citri tangerinae antithrombotic blocks patient's condition, plays treatment TIA thereby reverse the state of an illness; reducing the developing complete apoplexy of prevention generation significantly acts on.
Medicine of the present invention is made (consumption is a weight portion) by following component:
26～32 parts of 16～28 portions of Flos Sophorae Immaturus of 12～20 parts of Rhizoma Chuanxiongs of Pheretima
6～18 parts of 26～32 portions of Hirudos of Fructus Tribuli
The formula optimization weight proportion scope of preparation medicine of the present invention is:
26～30 parts of 18～26 portions of Flos Sophorae Immaturus of 12～18 parts of Rhizoma Chuanxiongs of Pheretima
6～12 parts of 26～30 portions of Hirudos of Fructus Tribuli
The optimum weight proportioning of medicine of the present invention is:
28 parts of 18 portions of Flos Sophorae Immaturus of 16 parts of Rhizoma Chuanxiongs of Pheretima
8 parts of 28 portions of Hirudos of Fructus Tribuli
Above-mentioned each component is made medicine production method of the present invention is:
1, water intaking trematodiasis rifle washing 10min after draining, places 50 ℃ of left and right sides continuous oven drying of calorstat, and moisture content is controlled in 3%～5%, and crushing screening is 120 order fine powders, ozone sterilization 20min, and airtight preservation is standby.
2, the Rhizoma Chuanxiong adding distil water is 28 times of medical material amount, soaks 1.5h, extracts 16h, collects volatile oil and fragrant medicinal liquid, adds antiseptic and stocks standby.
3, Pheretima Flos Sophorae Immaturus Fructus Tribuli and Rhizoma Chuanxiong are carried the medicinal residues behind the oil, add to boil to heat up in a steamer water group medicine and boil altogether, and amount of water is 12 times of medical material amount, soaks 1h, decocts 2 times, and 1.5h merging filtrate at every turn, filtrate is left standstill 12h.
4, get supernatant and carry the fragrant medicinal liquid in oil back and merge clear filter filtrate decompression and be concentrated into relative density 1.08,50 ℃ record, get concentrated solution, adding ethanol makes the volume fraction of alcohol reach 62%, place 12h, filtering precipitation filtrate recycling ethanol also is 1.32,25 ℃ and records thick extractum to not having the alcohol flavor, being evaporated to relative density.
5, thick extractum is placed about 50 ℃ oven dry of calorstat, moisture Control is that 120 order fine powders are standby with dried extractum piece crushing screening in 3%～5%.
6, get above-mentioned fine powder and adopt the equivalent multiplication method to add Hirudo powder, evenly spray into volatile oil, the airtight 6n of mix homogeneously, ozone sterilization 20min divides encapsulated.
Excellent characteristics of medicine of the present invention are to contain active ingredient fibrinolysin etc. in the medicament, has the expansion peripheral blood vessel, by suppressing nervous plain the synthesizing of blood plasma medium vessels, discharge, indirectly, distend the blood vessels, vascular resistance reduce and produce stable, lasting, keep blood flow demand balance, the effect of bringing high blood pressure down.
The excellent characteristics of another of medicine of the present invention are that medicament improves renal function and makes glomerular filtration rate, and renal blood flow significantly increases, and improving carbamide creatinine, phosphorus, sodium discharge capacity significantly increases.
The excellent characteristics of another of medicine of the present invention are to contain the active ingredient sodium ferulate in the medicament, cnidium lactone, hirudin etc., having has anti-hydrogen effect to smooth muscle, and by regulating prostaglandin and thromboxane system, activate the body fibrinolytic system, the accelerating fibers protein dissolution absorbs, and improves hematodinamics and rheology state, inhibiting erythrocyte aggregation, blood viscosity lowering, anticoagulant, expansion cardiovascular and cerebrovascular vessel, increase the heart and brain blood flow volume, improve the blood supply oxygen supply state of heart and brain tissues, reduce myocardial oxygen consumption, improve myocardial hypoxia tolerance, improve the erythrocyte electrophoresis rate, it is dense that reduction improves the blood height, high sticking, Gao Ning, high poly-" four height " state.Make the open tissue blood groundwater increment that increases of a large amount of blood capillaries, reduce cerebral vascular resistance, improve the permeability of blood brain barrier, anticoagulant suppresses thrombosis.
The excellent characteristics of another of medicine of the present invention are to contain active ingredient Fructus Tribuli glycoside in the medicament, rutin, Quercetins etc. have the lipid metabolism of improvement, hypercholesterolemia reducing, triglyceride, low density lipoprotein, LDL, its high density lipoprotein raises, correct lipoprotein or apolipoprotein metabolism disorder, prevent the deposition of lipid on blood vessel, prevent that arteriosclerosis from forming.
In a word, medicine medicine letter of the present invention is imitated grand, and the flat power of property is special, and whereabouts have to be worked as, push away Chen Zhixin, safe and effective, be a kind of desirable blood lipid metabolism of adjusting, balancing blood pressure reduces blood viscosity, atherosclerosis, improve clinical symptoms, control TIA, the natural Chinese medicines novel formulation of multiple actions such as minimizing prevention of brain apoplexy.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1, choice of drug pure natural animals and plants of the present invention are basic material, and each medicine name meets that " the Chinese pharmacopoeia title meets pharmaceutical control law, utilizes the comprehensive function treatment TIA of the Chinese medicine of respectively distinguishing the flavor of, and the prevention of brain apoplexy develops.
2, medicine of the present invention can be eliminated rapidly and improve the TIA symptom.
3, medicine of the present invention is suitable for and takes for a long time, and dosage is accurate, and dose is little, and is safe, no side reaction.
4, drug price of the present invention is reasonable, and is with low cost, is suitable for masses.
5, medicine of the present invention does not have GI irritation, better tolerance.
6, double hypertension, hyperlipemia, high blood clotting disease, coronary heart disease, arteriosclerosis, the arteriospasm etc. controlled of Drug therapy TIA of the present invention all have remarkable effectiveness.
For showing the anti-treatment fruit of medicine of the present invention, during in January, 1996～2002 year January, use medical treatment TIA of the present invention and carry out clinical research TIA.
1, data and method
1.1 diagnostic criteria
(1) tcm diagnosis standard: pass through " diagnosis of aurae of apoplexy and efficacy assessment standard " with reference in November, 1993 whole nation encephalopathy cooperative groups second session.
(2) Western medicine diagnose standard: with reference to U.S. apoplexy countermeasure coordination board (JCSF standard 1975) " diagnostic criteria of transient cerebral ischemic attack (TIA) ".
1.2 include the case standard in
All diagnosis that meets above-mentioned traditional Chinese medical science premonitory apoplexy and doctor trained in Western medicine TIA
(1) age was at 40～68 years old.(2) be of short duration, reversible, focal cerebral blood circulation obstacle, can show effect repeatedly, 1～2 time at least, tens of at most time, how relevant with arteriosclerosis, also but the prodrome of cerebral infarction.(3) show as the internal carotid artery system and (or) sings and symptoms of vertebra-matrix Arterial system.(4) show effect at every turn the persistent period usually several minutes to the 1h, sings and symptoms disappears in 24h.(5) brain CT or MRI check and get rid of other brain disorder.(6) there are hypertension history or present blood pressure to be higher than 160/95mmHg.(7) serum cholesterol, triglyceride, low density lipoprotein, LDL raise, and high density lipoprotein is anti-low.(8) arteriosclerosis.
Must possess in above-mentioned 1,2,3,4,5,6,7,85 can include in.
1.3 exclusion standard
(1) do not meet the above traditional Chinese medical science, Western medicine diagnose standard person.(2) all have severe cardiac, liver, a renal dysfunction person.(3) not medication in accordance with regulations can't be judged the incomplete or safety judgement person of curative effect person or data.
1.4 physical data
(1) group technology
Random packet is adopted in this test, and the method for double blind control (double blinding double dummy technique) is divided into treatment according to table of random number and organizes 60 examples, matched group 60 examples, male 42 examples are organized in treatment, women 18 examples, 43～69 years old age, average 50.6 ± 9.2 years old, the course of disease 0.6～12 year, average 6.4 ± 1.6 years; Clinical diagnosis: the TIA12 of internal carotid artery system example, vertebra one TIA39 of basilar artery system example, dual system TIA9 example, complication: hypertension 48 examples, hyperlipemia 51 examples, cerebral arteriosclerosis 39 examples, arteriospasm 29 examples, coronary heart disease 12 examples, diabetes 9 examples.Tcm syndrome differentiation and typing (1) hepatobiliary hyperactivity expectorant stasis of blood impatency 12 examples are contained in the wind-phlegm, obstruction of collaterals by blood stasis 30 examples, the deficiency of both QI and YIN venation stasis of blood 18 examples that stagnate.Each duration of seizure 4-56min surpasses 62min individually.Matched group man 39 examples, women 21 examples, age 43-68 year, average 51.2 ± 9.3 years old, course of disease 0.5-11, average 6.2 ± 1.4 years; Clinical diagnosis: the TIA9 of internal carotid artery system example, vertebra one basilar artery system 41 examples, dual system TIA10 example, complication: hypertension 46 examples, hyperlipemia 49 examples, cerebral arteriosclerosis 36 examples, arteriospasm 26 examples, coronary heart disease 10 examples, diabetes 7 examples; Tcm syndrome differentiation and typing (1) hepatobiliary hyperactivity expectorant stasis of blood impatency 13 examples are contained obstruction of collaterals by blood stasis 26 examples in the wind-phlegm, the deficiency of both QI and YIN venation stasis of blood 21 examples that stagnate.Each duration of seizure 6-52min surpasses 58min individually.
Two groups of patient's ordinary circumstances compare aspect sex, age, the course of disease, clinical diagnosis, complication, traditional Chinese medical science typing, and there was no significant difference has comparability (homogeneity check, P value are all＜0.05)
1.5 Therapeutic Method
1.5.1 the treatment group is developed natural Chinese medicines effective part extract (the main fibrinolysin, sodium ferulate, Quercetin of containing) packing Cheng Long rhizome of chuanxiong capsule with the institute of Chinese materia medica, Jincheng, Shanxi Province, every contains extract 360mg (being equivalent to crude drug 6.6g) 1/time, 1 time/d.
1.5.2 contrast level is divided in the capsule of same model with aspirin, every capsules contains aspirin 300mg, 1/time 1 time/d.
1.53 the course of treatment, 12mo was according to unified form and observation index, every 2mo follows up a case by regular visits to once, record TIA outbreak situation and clinical symptoms change situation.
1.6 observation index
1.6.1 safety observation
(1) general health check-up project, the untoward reaction that may occur.
(2) hematuria is just conventional, blood, urine, just routine test inspection before and after the treatment.
(3) heart, liver, kidney function test: carry out electrocardiogram, liver function (GPT) renal function (Bun, Cr) inspection before and after the treatment.
1.6.2 health giving quality inspection
(1) lab index: before and after observing in taking medicine early morning on an empty stomach (〉=12h), the forearm vein blood sampling is measured.(1) blood fat comprises TC, TG, HDL, LDL, uses enzymatic assays, finishes on the VITAAB automatic clinical chemistry analyzer.
(2) atherogenic index (AI)=TC-HKL-C/HDL-C.
(3) the blood flow mutilation contains items such as whole blood viscosity whole blood reduced viscosity, plasma viscosity, packed cell volume, fibronectin, erythrocyte sedimentation rate, adopts the rotary blood viscosity instrument of XBH-3 type cone-plate to measure, and has one unusually promptly to remember one "+".
(4) main clinic symptoms: adopt the classification scoring method to represent light and heavy degree and variation thereof.Asymptomatic or transference cure is remembered 0 fen; Symptom does not more influence work and rest, remembers 1 fen; Symptom is heavier, and still can restrain oneself has certain influence to work and rest, remembers 2 fens; Serious symptom is difficult to restrain oneself, and the work that influences is remembered 3 fens with rest.
1.7 statistical procedures
Test each parameter value with mean soil standard deviation (X ± S) expression, data relatively adopt the t check, enumeration data is checked with X2, ranked data relatively adopt Ridit to analyze.
2, result
2.1 curative effect judging standard
Clinical recovery: after observing 1y, TIA does not see outbreak, and symptoms such as dizzy limb fiber crops obviously disappear or alleviate, and TCD checks and has clear improvement.
Produce effects: the TIA seizure frequency obviously reduces, and the outbreak persistent period obviously shortens, and symptoms such as dizzy limb fiber crops obviously alleviate, and TCD checks improvement.
Effectively: the TIA seizure frequency reduces the outbreak persistent period and shortens, and symptoms such as dizzy, limb fiber crops alleviate to some extent, and TCD checks that idol has improvement.
Invalid: TIA seizure frequency no change increases outbreak, and the persistent period prolongs, and symptom does not have improvement, or complete apoplexy takes place.
2.2 tcm syndrome curative effect judging standard
Integration before the therapeutic index h=[(treatment-treatment back integration) integration before the ÷ treatment] * 100%
Clinical recovery 〉=90% produce effects 〉=70% effectively 〉=30% invalid＜30%
3, result
3.1 clinical efficacy treatment group total effective rate 98.3%, wherein clinical recovery 60%; Matched group total effective rate 68.4%, wherein 35%, two group of total effective rate of clinical recovery relatively has significant difference (X
2=19.44, P＜0.01) clinical recovery more also has significant difference (X
2=7.52, P＜0.01), and matched group has 11 examples that complete apoplexy take place, and the treatment group does not have 1 example and takes place.See Table 1
Table 1 liang group clinical efficacy relatively
| Curative effect | Treatment group (60%) | Matched group (60 example) |
| Clinical recovery produce effects enabledisable | 36(60％)· 16(26.7％)· 7(11.6％)· 1(1.7％) | 21(35％)· 18(30％) 2(3％) 19?31.6％ |
Annotate: compare P＜0.01 (following table together) with matched group
3.2 the clinical symptoms integrated value sees Table 2
Main clinic symptoms integrated value comparison before and after the table 2 liang group treatment (X ± S)
| Group h is not just having a headache the not smoothgoing puckery hemianesthesia stride of dizzy speech |
| 0.61 ± 0.07 △, 0.51 ± 0.05 △, 0.48 ± 0.04 △, 0.62 ± 0.07 △ convection potentials front 2.53 ± 0.91 2.13 ± 0.36 2.06 ± 0.98 2.12 ± 0.26 are according to 39 groups of treatments rear 2.41 ± 0.68 2.09 ± 0.61 1.99 ± 0.43 2.09 ± 0.76 after the front 2.5g for the treatment of ± 60 groups of treatments of 0.92 2.1 ± 10.81 2.04 ± 0.86 2.16 ± 0.91 treatment |
Annotate: with relatively P＜0.01 and matched group relatively △ P＜0.05 (following table with) before and after the treatment
3.3 changing, vertebral-basilar artery Vs sees Table 3
Table 3 liang group vertebral-basilar artery Vs variation (cm/s x ± s)
| Treatment group matched group |
| Control before the treatment after the furuncle before the treatment after the treatment |
| LVA????38.39±5.16????46.90±5.27·△????38.41±5.78?????4.02±4.92 RVA????37.92±4.93????45.88±5.69·△????38.01±5.62?????40.9±6.01 BA?????45.60±4.99????52.96±5.18·△????45.10±5.21?????47.20±52.9 |
3.4 the blood pressure changes in heart rate sees Table 4
Blood pressure changes in heart rate before and after the table 4 liang group treatment (x ± s)
| Group n systolic pressure mmhg diastolic pressure mmhg heart rate/min |
| Treat 50 groups of front 16.92 ± 18.2 98.6 ± 10.3 92.11 ± 12.6 treatments and treat rear 13.93 ± 16.2 △, 86.2 ± 9.1 △, 73.6 ± 9.1 △ convection potentials front 166.6 ± 17.3 98.2 ± 10.1 92.1 ± 12.5 according to 42 groups of treatments rear 146.2 ± 17.0 89.6 ± 10.6 76.4 ± 9.8 |
3.5 the blood index sees Table 5
The variation comparison of blood fat AI before and after the table 5 liang group treatment (mm01/2 x ± s)
| Group h TC TC HDL-C LDL-C AI |
| Treat 56 groups of front 6.90 ± 1.08 3.48 ± 2.70 0.86 ± 0.13 3.36 ± 1.23 3.73 ± 3.13 treatments and treat rear 4.96 ± 0.93 △, 2.35 ± 0.91 △, 1.69 ± 0.92 △ △, 2.83 ± 1.12 △ △ 2.991.02 △ convection potentials front 6.63 ± 0.96 3.22 ± 1.66 0.89 ± 0.14 3.62 ± 1.27 3.99 ± 1.49 according to 32 groups of treatments rear 5.92 ± 1.30 2.96 ± 1.37 1.06 ± 9.9 3.48 ± 1.24 3.69 ± 131 |
Annotate: with preceding relatively P＜0.005P＜0.01 of this group treatment
With comparison △ P＜0.05 △ △ P＜0.01 (following table together) after the treatment of control group
3.6 hemorheology index sees Table 6
Hemorheological indexes comparison before and after the table 6 liang group treatment (x ± s)
| After treating before the treatment of group n project |
| WBV (mpas) 6.96 ± 1.08 4.14 ± 0.62 △ control reduced viscosity (mpas) 6.65 ± 1.22 5.06 ± 1.02 △ and treat 6.51 ± 0.98 4.86 ± 0.68 pairs of reduced viscosities (mpas) of 60 plasma viscosities (mpas), 1.92 ± 0.25 1.36 ± 0.19 △ group fibrinogen (g/L) 4.21 ± 0.62 3.15 ± 0.31 △ packed cell volume (VOI) 0.48 ± 0.61 0.31 ± 0.28 △ erythrocyte sedimentation rate (mm/n), 23.96 ± 13.68 13.96 ± 11.26 △ WBVs (mpas) 6.68 ± 1.20 6.42 ± 1.31 according to 1.89 ± 0.60 1.69 ± 0.42 groups of fibrinogens (g/L) of 40 plasma viscosities (mpas), 3.97 ± 0.61 3.92 ± 0.58 packed cell volumes (VOI), 0.47 ± 0.74 0.45 ± 0.66 erythrocyte sedimentation rate (mm/n) 22.56 ± 13.28 21.62 ± 13.10 |
3.7 safety detection and untoward reaction
After reaching 1 year, in the clinical trial treatment group and matched group patient are advanced blood, urine, just routine, liver, the renal function Electrocardioscopy treatment no abnormal variation in front and back, also do not seen any untoward reaction.
Show from above-mentioned clinical research result: medicine energy enhancing body function of the present invention, anticoagulant, blood vessel dilating; remove fibre, increase the heart and brain blood flow, thrombolytic; blood pressure lowering improves the tremulous pulse Peripheral resistance, downgrades blood fat, balancing blood pressure; reduce blood viscosity, microcirculation improvement suppresses biologically active pdgf; the Fructus Citri tangerinae antithrombotic forms, and anti-tampon enlarges, and protects the heart and brain cell to a greater extent; treatment TIA reduces, blocks, reduces the incidence rate of SIE, thereby reduces case fatality rate and disability rate.
Embodiment
Take by weighing raw material by following proportioning
Pheretima 320g Rhizoma Chuanxiong 660g Flos Sophorae Immaturus 900g
Fructus Tribuli 900g Hirudo 108g
Get Hirudo rifle washing 10min.After draining, place calorstat, 50 ℃ of left and right sides continuous oven drying, moisture content is controlled in the 3%-5%, and crushing screening is 120 order fine powders, ozone sterilization 20min, airtight preservation is standby; Rhizoma Chuanxiong extracts volatile oil, and the adding distil water amount is 28 times of medical material amount, soaks 1.5h, extracts 16h, collects volatile oil and fragrant medicinal liquid adding antiseptic and stocks standby; The medicinal residues adding distil water group medicine that Pheretima Flos Sophorae Immaturus Fructus Tribuli and Rhizoma Chuanxiong are carried behind the oil is fried in shallow oil altogether, amount of water is 12 times of medicine village amount, soak 60min, decoct 2 times, each 90min, merging filtrate filters, filtrate is left standstill 12h, gets supernatant fragrance medicinal liquid and merges clear filter, and it is 1.08 that filtrate decompression is concentrated into relative density, 50 ℃ record concentrated solution, add ethanol and make the volume fraction of alcohol reach 62%, place 12h, the filtering precipitation, reclaim ethanol and extremely do not have the alcohol flavor, be evaporated to relative density and be 1.32,25 ℃ and record thick extractum, extractum is placed about 50 ℃ oven dry of calorstat, moisture content is controlled in the 3%-5%, is 120 order fine powders with dried extractum piece crushing screening; Get the medicine-feeding fine powder and adopt the equivalent multiplication method to add Hirudo powder, evenly spray into volatile oil, mix homogeneously, airtight 6h, ozone sterilization 20min divides encapsulated.
Claims (6)
1, active ingredient compositions in the pure natural animals and plants of a kind of treatment transient ischemic attack (TIA) is characterized in that by the Chinese medicine preparation of following materials of weight proportions through the preparation of modern Chinese medicine abstraction technique
26～32 parts of 20～28 portions of Flos Sophorae Immaturus of 12～20 parts of Rhizoma Chuanxiongs of Pheretima
6～18 parts of 26～32 portions of Hirudos of Fructus Tribuli
2, according to active ingredient compositions in the moving value of the pure natural thing of the described treatment of claim 1 TIA, it is characterized in that the weight proportion of raw material wherein is
26～30 parts of 22～26 portions of Flos Sophorae Immaturus of 12～18 parts of Rhizoma Chuanxiongs of Pheretima
6～12 parts of 26～30 portions of Hirudos of Fructus Tribuli
3, according to active ingredient compositions in the pure natural animals and plants of the described treatment of claim 1 TIA, wherein the weight proportion of each raw material is
28 parts of 18 portions of Flos Sophorae Immaturus of 16 parts of Rhizoma Chuanxiongs of Pheretima
8 parts of 28 portions of Hirudos of Fructus Tribuli
4, according to active ingredient compositions in the pure natural animals and plants of claim 1,2 or 3 described treatment TIA, it is characterized in that said pure Chinese medicinal preparation is said any dosage form in the pharmaceutical preparation.
5, according to active ingredient compositions in the pure natural animals and plants of the described treatment of claim 4 TIA, it is characterized in that said dosage form is a capsule.
6, active ingredient composition capsule preparation technology method in the pure natural animals and plants of the described treatment of claim 5 TIA, it is characterized in that getting Hirudo rifle washing 10min, after draining, place 50 ℃ of left and right sides continuous oven drying of calorstat, moisture content is controlled in 3%～5%, crushing screening is 120 order fine powders, ozone sterilization 20min, and airtight preservation is standby; Rhizoma Chuanxiong extracts volatile oil, and the adding distil water amount is 28 times of medical material amount, soaks 1.5h, extracts 16h, collects volatile oil and fragrant medicinal liquid adding antiseptic and stocks standby; Pheretima, the Flos Sophorae Immaturus, the medicinal residues adding distil water group medicine that Fructus Tribuli and Rhizoma Chuanxiong are carried behind the oil is fried in shallow oil altogether, amount of water is 12 times of medical material amount, soak 60min, decoct 2 times, each 90min, merging filtrate filters, filtrate is left standstill 12h, get supernatant and fragrant medicinal liquid merges clear filter, filtrate decompression is concentrated into relative density and records concentrated solution for 1.08 50 ℃, adds ethanol and makes the volume fraction of alcohol reach 62%, places 12h filtering precipitation, filtrate recycling ethanol also is evaporated to relative density and is 1.32 25 ℃ and records thick extractum to there not being the alcohol flavor, extractum is placed about 50 ℃ oven dry of calorstat, and moisture content is controlled in 3%～5%, is 120 order fine powders with dried extractum piece crushing screening; Get the medicine-feeding fine powder and adopt the equivalent multiplication method to add Hirudo powder, evenly spray into volatile oil, mix homogeneously, airtight 6h ozone sterilization 20min divides encapsulated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021256845A CN100453093C (en) | 2002-07-29 | 2002-07-29 | Medicine for transient cerebral ischemia attack and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021256845A CN100453093C (en) | 2002-07-29 | 2002-07-29 | Medicine for transient cerebral ischemia attack and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1471932A true CN1471932A (en) | 2004-02-04 |
| CN100453093C CN100453093C (en) | 2009-01-21 |
Family
ID=34143003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021256845A Expired - Fee Related CN100453093C (en) | 2002-07-29 | 2002-07-29 | Medicine for transient cerebral ischemia attack and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100453093C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102314707A (en) * | 2010-05-12 | 2012-01-11 | 微软公司 | Scanning beam depth map to the 2D image |
| CN105169216A (en) * | 2015-07-20 | 2015-12-23 | 冉宇欣 | Pharmaceutical preparation for treating transient ischemic attack with syndrome of blood stasis in orifices and preparation method of pharmaceutical preparation |
| CN105560746A (en) * | 2016-01-07 | 2016-05-11 | 陈彬 | Traditional Chinese medicine for treating transient ischemic attack caused by internal retention of phlegm and dampness and preparation method thereof |
| CN111166778A (en) * | 2019-12-31 | 2020-05-19 | 大连关爱糖尿病研究所有限公司 | Formula for treating lower limb arteriosclerosis obliterans (PAD) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1061882C (en) * | 1997-05-29 | 2001-02-14 | 廖宣盛 | Effective medicine for treating apoplexy |
-
2002
- 2002-07-29 CN CNB021256845A patent/CN100453093C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102314707A (en) * | 2010-05-12 | 2012-01-11 | 微软公司 | Scanning beam depth map to the 2D image |
| CN105169216A (en) * | 2015-07-20 | 2015-12-23 | 冉宇欣 | Pharmaceutical preparation for treating transient ischemic attack with syndrome of blood stasis in orifices and preparation method of pharmaceutical preparation |
| CN105560746A (en) * | 2016-01-07 | 2016-05-11 | 陈彬 | Traditional Chinese medicine for treating transient ischemic attack caused by internal retention of phlegm and dampness and preparation method thereof |
| CN111166778A (en) * | 2019-12-31 | 2020-05-19 | 大连关爱糖尿病研究所有限公司 | Formula for treating lower limb arteriosclerosis obliterans (PAD) |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100453093C (en) | 2009-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1259935C (en) | Medicine for treating hyperlipemia | |
| CN1965966A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN102309575B (en) | Application of medicinal composition in preparing medicament for treating diabetic complication | |
| CN108853433A (en) | A kind of Chinese medicine and preparation method thereof for treating diabetic nephropathy | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN1698804A (en) | Chinese medicinal preparation for treating qi obstruction in chest and heart palpitation and its preparation process | |
| CN1471932A (en) | Medicine for transient cerebral ischemia attack and its preparation | |
| CN1817354A (en) | Injection of manchurian wildginge and astragalus root and its preparing method | |
| CN102309632B (en) | Application of pharmaceutical composition in preparation of pharmaceuticals for treating complications of diabetes | |
| CN102397399B (en) | Application of traditional Chinese medicinal composition in preparation of medicament for controlling diabetes complications | |
| CN1087275A (en) | Treatment ischemic brain, cardiovascular preparation Shumaining | |
| CN101697989B (en) | Application of notoginseng and extract thereof in preparing medicaments for treating and/or preventing coronary artherosclerosis | |
| CN1839934A (en) | Chinese traditional medicine and its preparation method and use | |
| CN106109951A (en) | Prevent and treat medicine of hyperglycemia, hyperlipidemia, hypertension and preparation method thereof | |
| CN1520862A (en) | Prepared traditional Chinese medicine for apoplexy and obstruction of qi in the chest | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN1232283C (en) | Chinese drugs for treatment of coronary heart disease and angina pectoris | |
| CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
| CN1233361C (en) | Traditional Chinese medicine composition for treating cardiovascular disease | |
| CN1220504C (en) | Medicine for treating coronary disease and preparing method thereof | |
| CN1615956A (en) | Ginseng sini injection four treating cold limbs and preparing method | |
| CN1616009A (en) | Chinese medicine for treating high viscosity blood syndrome and its preparing method | |
| CN101549133B (en) | Ablation and embolism extinguishing preparation of Chinese medicine | |
| CN1140285C (en) | Medicine for treating high blood pressure and preventing cerebral hemorrhage and its preparing method | |
| CN1754546A (en) | Traditional Chinese medicine formulation for treating and preventing diabetes and its angiopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090121 |